Helix BioPharma Corp. (HBP : TSX)
Common Stock
$0.99
CAD
+0.00 (%)
Last updated: 2026-10-29
Follow HBP
HBP
Helix BioPharma Corp.
WealthAwesomePerformance
1 Day
+0.00%
1 Week
+1.02%
1 Month
-6.60%
YTD
-58.75%
Key Statistics
Market Cap
$75.61M
52W High
$2.60
52W Low
$0.82
P/E Ratio
-
50 Day MA
$1.33
200 Day MA
$1.65
Beta
-0.14
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/29/2026 | $0.99 | $0.99 | $0.99 | $0.99 | $0.99 | 0 |
| 10/28/2026 | $0.96 | $0.99 | $0.96 | $0.99 | $0.99 | 207 |
| 10/27/2026 | $1.04 | $1.10 | $0.98 | $1.04 | $1.04 | 5,459 |
| 10/26/2026 | $0.85 | $1.00 | $0.85 | $0.99 | $0.99 | 12,165 |
| 10/23/2026 | $0.88 | $0.88 | $0.82 | $0.82 | $0.82 | 14,135 |
| 10/22/2026 | $0.98 | $0.98 | $0.98 | $0.98 | $0.98 | 0 |
| 10/21/2026 | $0.91 | $0.98 | $0.90 | $0.98 | $0.98 | 9,500 |
| 10/20/2026 | $0.98 | $0.98 | $0.98 | $0.98 | $0.98 | 0 |
| 10/19/2026 | $0.98 | $0.98 | $0.98 | $0.98 | $0.98 | 0 |
| 10/16/2026 | $0.93 | $0.99 | $0.93 | $0.98 | $0.98 | 10,000 |
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 152.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+152.5% Upside
Current Price
C$0.99
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
124.9%
Annualized
90-Day Vol
89.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.83
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.93 | C$0.61 – C$1.44 |
| 60 trading days | C$0.88 | C$0.48 – C$1.62 |
| 90 trading days | C$0.83 | C$0.39 – C$1.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-3.25M
- Profit Margin
- 0.00%
- ROE (TTM)
- -49.99%
- EPS (Diluted)
- -0.04
- Book Value
- 0.19
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
🔄 Recent Splits
1-for-5
Aug 16, 2024
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About HBP
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| PNC-B | Postmedia Network Canada Corp | $0.15 | +50.00% |
| SLT | Saltire Capital Ltd. | $2.65 | +32.50% |
| BHC | Bausch Health Companies Inc | $12.41 | +28.34% |
| PNC-A | Postmedia Network Canada Corp | $0.14 | +20.83% |
| LUC | Lucara Diamond Corp | $0.13 | +18.18% |
| BNG | Bengal Energy Ltd | $0.04 | +14.29% |
| KLS | Kelso Technologies Inc | $0.14 | +12.00% |
| GRC | Gold Springs Resource Corp | $0.05 | +11.11% |
HBP.TO news timeline
15 articles covering HBP.TO, most recent first
LatestWill Helix BioPharma Corp. (HBP) Beat Earnings Estimates in Its Next Report?
October 2026
- Why Helix BioPharma Corp. stock is rising today
- What's Going On With Helix BioPharma Corp. Stock Friday?
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock went up yesterday
- Why Helix BioPharma Corp. stock went up yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday
September 2026
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock surged yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday
- What's Going On With Helix BioPharma Corp. Stock Tuesday?
- Why Helix BioPharma Corp. stock fell yesterday
- What's Going On With Helix BioPharma Corp. Stock Monday?
- Why Helix BioPharma Corp. stock plummeted yesterday